What the science actually shows.
Every research summary here is written to the same standard. We report what studies show — including their limitations. We do not select studies for their conclusions. We do not present preliminary findings as established science. We do not omit conflicting evidence.
The research landscape for BPC-157 and TB-500 is substantial. Studies have demonstrated meaningful effects on tendon and ligament healing, muscle repair, bone healing, gastrointestinal tissue repair, neurological tissue protection, and systemic inflammatory modulation. The majority of studies have been conducted in preclinical models. Human clinical trials are ongoing. The mechanistic evidence is strong. The human outcome data continues to develop. We will never overstate what the science shows.
The secretagogue category carries one of the strongest research foundations in this space — driven by decades of clinical use in age-related growth hormone decline and pediatric growth disorders. Research demonstrates meaningful effects on lean muscle mass preservation, adipose tissue reduction particularly visceral fat, improved recovery time, enhanced slow wave sleep quality, bone mineral density support, and metabolic rate optimization. Sermorelin carries the longest established clinical record. CJC-1295 and Ipamorelin combination data continues to expand.
The GLP receptor agonist class carries the most robust clinical evidence base of any category in the Veridyn Forma™ catalog. This is not emerging science. It is established, peer-reviewed, FDA-recognized pharmacology with decades of development. Clinical trials demonstrate sustained body weight reduction far exceeding diet and exercise interventions, visceral fat reduction, insulin sensitivity improvement, cardiovascular risk reduction independent of weight loss, appetite normalization, and sustained outcomes. The evidence base is substantial and expanding.
Neuropeptide research spans decades — driven initially by clinical applications in neurological injury, stroke recovery, and neurodegenerative disease. Research demonstrates effects on working memory, sustained attention, learning speed, processing speed, stress resilience, BDNF elevation, neuroprotection markers, and mood stability. The BDNF elevation produced by Semax is one of the most significant and well-documented neurobiological effects in this category. Human clinical data continues to expand beyond the neurological rehabilitation context.
The longevity peptide category carries a research foundation that is simultaneously one of the deepest and most underappreciated in modern biology. Four decades of Epithalon research demonstrate telomere length effects, epigenetic age marker shifts, and lifespan extension in multiple model organisms. Bioregulator peptide research demonstrates measurable immune cell population improvements and reduced senescence markers. Human longevity outcome data — by its nature requiring decades of follow-up — remains an active and expanding frontier. What we know is strong. What we are still learning is vast. We will tell you both.
PT-141 carries FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women — one of the most significant clinical validations in this catalog. Clinical trials demonstrate efficacy across both male and female populations through central neurological desire pathways that represent a genuine advance over peripheral approaches. MT-2 research demonstrates spontaneous arousal induction, erectile function support, and well-characterized pigmentation effects. Dose titration is important for MT-2 given its broader receptor activation profile and associated side effect considerations.
Thymosin Alpha-1 carries the most established clinical evidence base of any compound in the Fortis™ category — with medical applications across more than 35 countries including hepatitis B treatment, hepatitis C treatment, and adjunctive cancer therapy. Research demonstrates T cell function restoration, enhanced NK cell activity, improved vaccine response, direct antiviral effects, and reduced inflammatory markers. The evidence is not preliminary. It is decades deep.
GHK-Cu carries one of the most substantial research foundations of any cosmetic active compound in scientific literature — with studies spanning tissue culture, animal models, and human clinical trials across five decades. Research demonstrates statistically significant increases in collagen production, measurable increases in dermal skin thickness, improved biomechanical properties of treated skin, measurable reduction in fine line depth, wound healing acceleration, and documented influence on expression of more than 4000 human genes relevant to tissue repair. The cosmetic peptide research in this category is not marketing science. It is established molecular biology.